BankInvest Biomedical Venture
VC Fund
BankInvest Biomedical Venture is a VC fund focused on Biotechnology and Health Care. BankInvest Biomedical Venture makes investments in research-based biotechnology companies in Europe.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries BankInvest Biomedical Venture invests in
Stages BankInvest Biomedical Venture invests in
Countries BankInvest Biomedical Venture invests in
Round sizes
Round size
- Series B
- $8M–$8.8M
- Series C
- $6.1M–$14M
Investment Focus
Industry
- Biotechnology 7 (78%)
- Health Care 6 (67%)
- Medical 4 (44%)
- Pharmaceutical 3 (33%)
- Biopharma 2 (22%)
Stage
- Funding Round 3 (33%)
- Series B 2 (22%)
- Series C 2 (22%)
- Series D 1 (11%)
Country
- Denmark 2 (22%)
- United Kingdom 2 (22%)
- France 1 (11%)
- Sweden 1 (11%)
- United States 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversifiedinto chemistry-driven discovery. They have also assembled an experienced development capacity. | $8M / Aug 18, 2008 | ||
| Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent forthe treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California. | $45M / Series D / Aug 09, 2007 | ||
Resistentia Pharmaceuticals
|
Resistentia Pharmaceuticals, a biopharmaceutical company, develops immunotherapeutic products for allergic asthma and inflammatory disorders. It provides Immunoglobulin E for allergic reactions, including asthma, rhinitis, and dermatitis; and C5a for the treatment of inflammatory conditions, such as rheumatoid arthritis, asthma, and multiplesclerosis. Resistentia Pharmaceuticals AB was founded in 1998 and is based in Uppsala, Sweden. | $14M / Series C / Sep 26, 2006 | |
| Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers.Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologicmalignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications. | $6.1M / Series C / Jun 01, 2005 | ||
| LiPlasome is a Danish privately owned biotech company focusing on oncology. The LiPlasome technology provides a liplasomal reformulation of the most used anticancer drugs on the market like Cispaltin -> LiPlaCis®, Oxaliplatin -> LiPloxa. The aim is to provide more effective treatment to cancer patients with fewer side effects. | $8M / Series B / Mar 01, 2005 | ||
| Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers.Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologicmalignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications. | $8.8M / Series B / May 01, 2002 | ||
| Oxagen Limited, a biopharmaceutical company, provides drug discovery and development solutions. It offers molecule drugs for the treatment of asthma, autoimmune disease, inflammatory bowel, psoriasis, allergy, and rheumatoid arthritis diseases. Oxagen Limited was founded in 1997 and is based in Abingdon, the United Kingdom. | $39.3M / Dec 21, 2000 | ||
| Genmab is an international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's discovery, development, and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Its primary goal is to improve the lives ofpatients who are in urgent need of new treatment options. | $40.5M / Jun 13, 2000 | ||
| Genmab is an international biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer. Genmab's discovery, development, and manufacturing teams are using cutting-edge technology to create and develop products to address unmet medical needs. Its primary goal is to improve the lives ofpatients who are in urgent need of new treatment options. | $2M / May 17, 1999 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does BankInvest Biomedical Venture invest in?
BankInvest Biomedical Venture invests primarily in Biotechnology, Health Care and Medical startups, most often at Funding Round and Series B stage. Most of the 9 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is BankInvest Biomedical Venture's check size?
BankInvest Biomedical Venture typically joins rounds of $8M–$8.8M at Series B and $6.1M–$14M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BankInvest Biomedical Venture participates in.
When did BankInvest Biomedical Venture last invest?
The most recent investment recorded for BankInvest Biomedical Venture closed in Aug 2008. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
